461 related articles for article (PubMed ID: 11897578)
1. In vitro and in vivo activities of anti-influenza virus compound T-705.
Furuta Y; Takahashi K; Fukuda Y; Kuno M; Kamiyama T; Kozaki K; Nomura N; Egawa H; Minami S; Watanabe Y; Narita H; Shiraki K
Antimicrob Agents Chemother; 2002 Apr; 46(4):977-81. PubMed ID: 11897578
[TBL] [Abstract][Full Text] [Related]
2. [Favipiravir, a new concept of antiviral drug against influenza viruses].
Reina J; Reina N
Rev Esp Quimioter; 2017 Apr; 30(2):79-83. PubMed ID: 28176519
[TBL] [Abstract][Full Text] [Related]
3. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
Takashita E; Ejima M; Ogawa R; Fujisaki S; Neumann G; Furuta Y; Kawaoka Y; Tashiro M; Odagiri T
Antiviral Res; 2016 Aug; 132():170-7. PubMed ID: 27321665
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
Takahashi K; Furuta Y; Fukuda Y; Kuno M; Kamiyama T; Kozaki K; Nomura N; Egawa H; Minami S; Shiraki K
Antivir Chem Chemother; 2003 Sep; 14(5):235-41. PubMed ID: 14694986
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
Sidwell RW; Barnard DL; Day CW; Smee DF; Bailey KW; Wong MH; Morrey JD; Furuta Y
Antimicrob Agents Chemother; 2007 Mar; 51(3):845-51. PubMed ID: 17194832
[TBL] [Abstract][Full Text] [Related]
6. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
Sleeman K; Mishin VP; Deyde VM; Furuta Y; Klimov AI; Gubareva LV
Antimicrob Agents Chemother; 2010 Jun; 54(6):2517-24. PubMed ID: 20350949
[TBL] [Abstract][Full Text] [Related]
7. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
[TBL] [Abstract][Full Text] [Related]
8. Plaque inhibition assay for drug susceptibility testing of influenza viruses.
Hayden FG; Cote KM; Douglas RG
Antimicrob Agents Chemother; 1980 May; 17(5):865-70. PubMed ID: 7396473
[TBL] [Abstract][Full Text] [Related]
9. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.
Leneva IA; Roberts N; Govorkova EA; Goloubeva OG; Webster RG
Antiviral Res; 2000 Nov; 48(2):101-15. PubMed ID: 11114412
[TBL] [Abstract][Full Text] [Related]
10. Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
Furuta Y; Gowen BB; Takahashi K; Shiraki K; Smee DF; Barnard DL
Antiviral Res; 2013 Nov; 100(2):446-54. PubMed ID: 24084488
[TBL] [Abstract][Full Text] [Related]
11. [Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models].
Leneva IA; Fediakina IT; Eropkin MIu; Gudova NV; Romanovskaia AA; Danilenko DM; Vinogradova SM; Lepeshkin AIu; Shestopalov AM
Vopr Virusol; 2010; 55(3):19-27. PubMed ID: 20608077
[TBL] [Abstract][Full Text] [Related]
12. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
[TBL] [Abstract][Full Text] [Related]
14. Geniposide demonstrates anti-inflammatory and antiviral activity against pandemic A/Jiangsu/1/2009 (H1N1) influenza virus infection in vitro and in vivo.
Zhang Y; Yao J; Qi X; Liu X; Lu X; Feng G
Antivir Ther; 2017; 22(7):599-611. PubMed ID: 28272019
[TBL] [Abstract][Full Text] [Related]
15. Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model.
Pascua PNQ; Marathe BM; Vogel P; Webby RJ; Govorkova EA
J Antimicrob Chemother; 2019 May; 74(5):1333-1341. PubMed ID: 30715325
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of activity against influenza viruses by combinations of antiviral agents.
Hayden FG; Douglas RG; Simons R
Antimicrob Agents Chemother; 1980 Oct; 18(4):536-41. PubMed ID: 7447417
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions.
Brooks MJ; Burtseva EI; Ellery PJ; Marsh GA; Lew AM; Slepushkin AN; Crowe SM; Tannock GA
J Med Virol; 2012 Jan; 84(1):170-81. PubMed ID: 22028179
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of T-705 against influenza virus.
Furuta Y; Takahashi K; Kuno-Maekawa M; Sangawa H; Uehara S; Kozaki K; Nomura N; Egawa H; Shiraki K
Antimicrob Agents Chemother; 2005 Mar; 49(3):981-6. PubMed ID: 15728892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
